{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:03:19Z","timestamp":1789498999008,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jgar.2020.01.014","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T11:42:16Z","timestamp":1580384536000},"page":"78-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["In vitro synergy with fosfomycin plus doxycyclin against linezolid and vancomycin-resistant Enterococcus faecium"],"prefix":"10.1016","volume":"22","author":[{"given":"Heather","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ashcraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pankey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.01.014_bib0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2020.01.014_bib0010","series-title":"Vancomycin-Resistant Enterococci (VRE) Overview","author":"National Institute of Allergy and Infectious Diseases","year":"2009"},{"issue":"S1","key":"10.1016\/j.jgar.2020.01.014_bib0015","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1093\/ofid\/ofy344","article-title":"Temporal and geographic variation in antimicrobial susceptibility and resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.014_bib0020","series-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2019"},{"issue":"1079","key":"10.1016\/j.jgar.2020.01.014_bib0025","first-page":"45","volume":"42","author":"Linezolid","year":"2000","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.jgar.2020.01.014_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.04.002","article-title":"Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms","volume":"17","author":"Mendes","year":"2014","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.jgar.2020.01.014_bib0035","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid surveillance results for the United States (LEADER Surveillance Program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"36","key":"10.1016\/j.jgar.2020.01.014_bib0040","doi-asserted-by":"crossref","first-page":"13339","DOI":"10.1073\/pnas.0804276105","article-title":"The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning","volume":"105","author":"Wilson","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.jgar.2020.01.014_bib0045","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1128\/AAC.46.10.3334-3336.2002","article-title":"Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis","volume":"46","author":"Marshall","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.jgar.2020.01.014_bib0050","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1128\/AAC.48.9.3583-3585.2004","article-title":"Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin","volume":"48","author":"Raad","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jgar.2020.01.014_bib0055","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1086\/513876","article-title":"Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo","volume":"195","author":"Bourgeois-Nicolaos","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.014_bib0060","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1128\/AAC.01473-15","article-title":"Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium isolates recovered from human specimens in the United States as part of the SENTRY Antimicrobial Surveillance Program","volume":"59","author":"Deshpande","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.01.014_bib0065","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1093\/jac\/dkv116","article-title":"A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin","volume":"70","author":"Wang","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.jgar.2020.01.014_bib0070","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/jac\/dky088","article-title":"Characterization of poxtA, a novel phenicol\u2013oxazolidinone\u2013tetracycline resistance gene from an MRSA of clinical origin","volume":"73","author":"Antonelli","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.01.014_bib0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2020.01.014_bib0080","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/clinids\/14.6.1173","article-title":"Emergence of Enterococcus as a Significant Pathogen","volume":"14","author":"Moellering","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.014_bib0085","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1974.tb43277.x","article-title":"The mechanism of action of fosfomycin (phosphomycin)","volume":"235","author":"Kahan","year":"1974","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jgar.2020.01.014_bib0090","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.02099-12","article-title":"Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents","volume":"57","author":"Descourouez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.01.014_bib0095","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diagmicrobio.2013.07.012","article-title":"In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates","volume":"77","author":"Tang","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.014_bib0100","first-page":"471","article-title":"Safety and efficacy review of doxycycline","volume":"1","author":"Holmes","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2020.01.014_bib0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","article-title":"Persistent extended-spectrum \u03b2-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline","volume":"45","author":"Cunha","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.01.014_bib0110","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1128\/AAC.46.5.1319-1324.2002","article-title":"Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci","volume":"46","author":"Eliopoulos","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.01.014_bib0115","unstructured":"FDALabel. US Food and Drug Administration. https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/search. [Accessed 4 December 2019]."},{"issue":"3","key":"10.1016\/j.jgar.2020.01.014_bib0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/clinids\/24.3.457","article-title":"Oral administration of antibiotics: a rational alternative to the parenteral route","volume":"24","author":"MacGregor","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.014_bib0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2020.01.014_bib0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1179\/joc.2005.17.Supplement-1.12","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline","volume":"17","author":"Rello","year":"2005","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2020.01.014_bib0135","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019"},{"key":"10.1016\/j.jgar.2020.01.014_bib0140","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"10.1016\/j.jgar.2020.01.014_bib0145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.diagmicrobio.2013.07.006","article-title":"Comparison of 3 Etest\u00ae methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species","volume":"77","author":"Pankey","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.014_bib0150","series-title":"Antibiotics in Laboratory Medicine","first-page":"365","article-title":"Antimicrobial Combinations","author":"Pillai","year":"2005"},{"key":"10.1016\/j.jgar.2020.01.014_bib0155","series-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved guideline. NCCLS document M26-A","author":"National Committee for Clinical Laboratory Standards","year":"1999"},{"key":"10.1016\/j.jgar.2020.01.014_bib0160","series-title":"EUCAST reading guide for broth microdilution","author":"European Committee on Antimicrobial Susceptibility Testing [EUCAST]","year":"2019"},{"key":"10.1016\/j.jgar.2020.01.014_bib0165","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/AAC.00589-13","article-title":"In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: Establishing the validity of standard broth microdilution as susceptibility testing method","volume":"57","author":"D\u00edez-Aguilar","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.01.014_bib0170","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1128\/AAC.02237-15","article-title":"Is a new standard needed for diffusion methods for in vitro susceptibility testing of fosfomycin against Pseudomonas aeruginosa?","volume":"60","author":"D\u00edez-Aguilar","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520300151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520300151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:00Z","timestamp":1761990900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520300151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"alternative-id":["S2213716520300151"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.01.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro synergy with fosfomycin plus doxycyclin against linezolid and vancomycin-resistant Enterococcus faecium","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}